Home/Biosimilar Atlas/Filgrastim/Gennova filgrastim

Gennova filgrastim

Filgrastim biosimilar developed by Gennova Biopharmaceuticals (Emcure). Reference product Neupogen.

Brands by market: Brand not published by CDSCO (India) · Commercial partner or holder: Gennova Biopharmaceuticals · Company profile
FDANot listed
EMANot listed
MHRANot listed
PMDANot listed
HCNot listed
CDSCOMar 2010permitted
EDENot listed
Approved or registered in 1 of 7 markets
Connections
FilgrastimmoleculeGennova Biopharmaceuticalsdeveloper1 of 7markets0trials behind it1other products, same developer2rival developers in its markets

About Gennova filgrastim

Gennova received its filgrastim permission in India in March 2010, two months after its pegfilgrastim. Gennova, part of Emcure, is a Pune-based biologics maker.

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union

Not listed by EMA.

MHRA

United Kingdom

Not listed by MHRA.

PMDA

Japan

Not listed by PMDA.

HC

Canada

Not listed by HC.

CDSCO

India

Central Drugs Standard Control OrganisationApproved
Brand
Not published by CDSCO (INN only)
Holder or applicant
Gennova Biopharmaceuticals Ltd
Pathway
Similar Biologic, manufacture and marketing permission
Approved
Mar 2010
Application or permission
MF-229/10
Indications as licensed
Cancer patients receiving myelosuppressive therapy
Presentations
PFS and vial
Source
S014 (CDSCO) · checked Sep 2026
EDE

United Arab Emirates

Not listed by EDE.

Other developers in the same markets

Where Gennova filgrastim holds an approval, these are the other filgrastim biosimilars approved in that market.

MarketRivalsDevelopers (product)
CDSCO2Cadila Pharmaceuticals (Cadila Pharmaceuticals filgrastim), Lupin (Lupin filgrastim)

Same developer, other molecules

Other biosimilars in the Atlas developed by Gennova Biopharmaceuticals: Gennova pegfilgrastim.

Chronology

Sources

All filgrastim biosimilars

Planning filgrastim biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.